Celebrex Antitrust Litigation
Court: United States District Court, Eastern District of Virginia
In Re: CELEBREX (CELECOXIB) ANTITRUST LITIGATION, Case No: 14-cv-0395
Leadership Position: Co-Lead Class Counsel
Wexler Wallace LLP is Interim Co-Lead Counsel for the end purchaser plaintiffs (consumers and third party payors) in an antitrust class action against Pfizer Inc. and its subsidiaries involving the blockbuster drug Celebrex. The plaintiffs allege that Pfizer unlawfully prolonged its monopoly over Celebrex by fraudulently obtaining a patent claiming the celecoxib compound, which Pfizer then asserted against potential generic competitors in baseless patent infringement lawsuits. The plaintiffs have alleged that Pfizer’s conduct caused consumers and drug benefit plans to pay more for Celebrex and its generic equivalents than they otherwise would have.
To view a copy of the consolidated amended complaint, click here.